Serial pulmonary function in systemic sclerosis

https://doi.org/10.1016/0002-9343(82)90732-XGet rights and content

Abstract

The natural history of the pulmonary involvement in systemic sclerosis is not well studied. Reported here are the serial measurements of pulmonary function in a well defined population of patients with systemic sclerosis followed over a mean of 63 months. The mean rate of loss of vital capacity (0.10 liters per year) for the 38 patients serially studied was more than three times the expected rate of loss for a normal population. The mean rate of loss of diffusing capacity (0.33 ml/min/mm Hg per year) for the 27 patients serially studied was similar to that for a normal population. The percent forced vital capacity expired in the first second increased 0.53 percent per year consistent with a progressive restrictive ventilatory defect. Smokers tended to lose vital capacity at a slightly greater rate than nonsmokers (p = 0.069). Individual variability in the course of pulmonary function was observed. Although the overall trend in our population was towards a slowly progressive restrictive ventilatory defect, pulmonary function in the nonsmokers did not change at rates different from those in a nonsmoking reference population.

Reference (28)

  • WeaverAL et al.

    The lung in scleroderma

  • SacknerMA et al.

    The pathophysiology of scleroderma involving the heart and respiratory system

    Ann Intern Med

    (1964)
  • DemuthGR et al.

    Pulmonary manifestations of progressive systemic sclerosis

    Am J Med Sci

    (1968)
  • GuttadauriaM et al.

    Pulmonary function in scleroderma

    Arthritis Rheum

    (1977)
  • Cited by (68)

    • Association between cigarette smoking and impaired clinical symptoms in systemic sclerosis: A review

      2017, Cellular Immunology
      Citation Excerpt :

      Greenwald et al. [28] demonstrated that nonsmokers had greater rates of decline in total lung capacity and static lung compliance than did current and former smokers. Some other authors have also reported that pulmonary function in nonsmokers was not different and that it did not change at rates different from those in a nonsmoking reference population [29]. This means that individual variability in the course of pulmonary function is large and not completely explained by smoking status.

    • Connective Tissue Diseases

      2015, Murray and Nadel's Textbook of Respiratory Medicine: Volume 1,2, Sixth Edition
    • Pulmonary function tests in interstitial lung disease: What role do they have?

      2001, Clinics in Chest Medicine
      Citation Excerpt :

      In contrast, Bagg and Hughes20 noted gradual progression of restrictive abnormality. A similar gradual progression was reported by Schneider et al,290 who performed serial PFTs in 38 patients followed over a mean of 63 months. The overall trend was of a slowly progressive restrictive defect; the mean rate of loss in FVC was more than three times the normal rate of FVC loss.

    • Pulmonary-renal syndrome in systemic sclerosis

      2001, Seminars in Arthritis and Rheumatism
    View all citing articles on Scopus

    This study was supported in part by an Arthritis Foundation Clinical Research Center Grant and the Johns Hopkins Multipurpose Arthritis Center Grant 2-P60-AM20588.

    1

    From the Divisions of Rheumatology and Respiratory Medicine, Department of Medicine, Johns Hopkins University School of Medicine at the Good Samaritan Hospital, Baltimore, Maryland.

    View full text